4th Annual ASH 2018 Updates: Practice Changing Abstracts by Meeting Achievements

4th Annual ASH 2018 Updates: Practice Changing Abstracts is organized by Meeting Achievements and will be held on Feb 15, 2019 at University of Chicago - Gleacher Center, Chicago, Illinois, United States of America.

The target audience for this medical event is physicians and other healthcare professionals interested in the treatment of hematologic cancers. This CME Conference has been approved for a maximum of 3.75 AMA PRA Category 1 Credits.

Course Description:
Patients in medically underserved communities have limited access to subspecialty care. Community-based oncologists are well positioned to provide initial care for these patients, but often do not have the knowledge and confidence to manage difficult cases. According to the 2015 Community Health Needs Assessment, between 2006 and 2008, the City of Chicago experienced an annual average adjusted cancer mortality rate of 194.2 deaths per 100,000 individuals. Cancer mortality has de-creased over the past decade in Cook County; the same trend is apparent both statewide and nationwide. Although both trends are decreasing, Cook County cancer related mortality is greater than the national average deaths per 100,000 individuals. Also, city of Chicago cancer mortality rates are higher than regional, state, and national cancer death rates. University experts in hematological cancers agree that we need to join our regional cancer community to lower our county and state mortality rate. This is similar throughout all states. Also, many local health professionals do not have the time or resources available to attend the annual updates from ASH 2018 conference where the latest scientific and clinical research in blood cancers is discussed, so they need a venue in which they can learn about these important updates.

Course Objectives:
• Cite how understanding the biology of different types of leukemia has influenced treatment approaches;
• Describe next generation improvements in CAR T-cell therapies;
• Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
• List current best practices in first and second line therapies for lymphoid malignancies;
Name new technologies used for the treatment of hemophilia;
• Interpret how new scientific insights are informing the diagnosis and treatment of myelodysplastic syndromes and myeloproliferative neoplasms.

Additional details will be posted as soon as they are available.